| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T320 |
0-57 |
Sentence |
denotes |
Imatinib Mesylate (Gleevec (US)/Glivec (Europe/Australia) |
| T321 |
58-159 |
Sentence |
denotes |
(Novartis) Well absorbed; absolute bioavailability=98%; maximum plasma levels within 2-4 h of dosing; |
| T322 |
160-177 |
Sentence |
denotes |
Vd= 347 l (+/-62) |
| T323 |
178-408 |
Sentence |
denotes |
(198) Metabolized mainly by hepatic CYP3A4 and to a lesser extent by CYP1A2, CYP2D6, CYP2C9, CYP2C19 400 mg orally daily (chronic myeloid leukemia (chronic phase); 600 mg orally daily (chronic myeloid leukemia (accelerated phase); |
| T324 |
409-708 |
Sentence |
denotes |
95% binding (AAG, HSA) Most pulmonary toxicities associated with imatinib are related to fluid retention, with peripheral and periorbital edema more common than pleural or pericardial effusions and pulmonary edema; acute pneumonia and subacute interstitial pneumonitis occur rarely (199) (200) (201) |
